SELLAS Life Sciences Group (AMEX:SLS)‘s stock had its “buy” rating reaffirmed by equities research analysts at Maxim Group in a research report issued on Friday, Price Targets.com reports. They currently have a $12.00 price objective on the biotechnology company’s stock.
SELLAS Life Sciences Group (AMEX:SLS) last announced its earnings results on Thursday, May 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.11.
SELLAS Life Sciences Group Company Profile
Recommended Story: Most Active Stocks
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.